Loading
CIC (Protein capicua homolog) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Lung cancer, Pancreatic ductal adenocarcinoma and 4 more.
Transcriptional repressor which plays a role in development of the central nervous system (CNS). In concert with ATXN1 and ATXN1L, involved in brain development.
CIViC holds 11 clinical evidence items and 0 assertions across 3 variants, naming Trametinib, Vemurafenib and Selumetinib. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.76, genetic association 0.00, somatic mutation 0.85). IntOGen calls it a driver in 4 cohorts (1 activating, 3 loss-of-function), covering Hepatocellular Carcinoma, Low-Grade Glioma, NOS, Lung Adenocarcinoma.
In plain words · CIC (Protein capicua homolog) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Lung cancer, Pancreatic ductal adenocarcinoma and 4 more.
CIC (Protein capicua homolog) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Lung cancer, Pancreatic ductal adenocarcinoma and 4 more.
Transcriptional repressor which plays a role in development of the central nervous system (CNS). In concert with ATXN1 and ATXN1L, involved in brain development.
No product in this corpus aims at CIC yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CIC: RNA low tissue specificity; high antibody staining in 2 normal tissues; highest cancer staining breast cancer (8 of 10 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Colorectal cancer, Lung cancer (all types), Pancreatic ductal adenocarcinoma, Hepatocellular carcinoma, Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q96RK0; CIViC gene CIC; IntOGen CIC; Human Protein Atlas CIC tissue; Open Targets ENSG00000079432 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Nagase et al, DNA Res, 1997, "Prediction of the coding sequences of unidentified human genes. VII. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro". Source.
Sources: HGNC HGNC:14214 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q96RK0 (protein name, function text, keywords and locations (REST API)); CIViC gene CIC (11 evidence items, 0 assertions, 3 variants; diseases: Lung Cancer, Melanoma, Colon Cancer, Pancreatic Cancer (GraphQL API, CC0)); Open Targets ENSG00000079432 (association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: colorectal cancer 0.54, melanoma 0.55, skin cancer 0.56 (GraphQL API, CC0)); IntOGen CIC (driver in 4 cohorts (Act 1, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcriptional repressor which plays a role in development of the central nervous system (CNS). In concert with ATXN1 and ATXN1L, involved in brain development. Location: Nucleus (UniProt). Locus 19q13.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adrenal gland, Appendix, Bone marrow, Breast, Bronchus, Caudate, Cerebellum, Cervix.
Medium only: carcinoid, head and neck cancer, liver cancer, lymphoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CIC" OR ABSTRACT:"CIC" OR TITLE:"capicua transcriptional repressor" OR ABSTRACT:"capicua transcriptional repressor" OR TITLE:"Protein capicua homolog" OR ABSTRACT:"Protein capicua homolog" OR TITLE:"KIAA0306" OR ABSTRACT:"KIAA0306") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CIC, not a curated reading list.